| abstract |
The present invention relates to new fusion protein binding domain immunoglobulins, which are characterized in that they contain a binding domain for a recognizable structure, such as an antigen, a contraceptor or the like; a region acting as a wild-type IgG, IgA or IgE hinge region, i.e., an IgE CH2 polypeptide or a mutant IgGI hinge polypeptide lacking cysteine residues or having one or two cysteine residues, and immunoglobulin CH2 and CH3 domains that are capable of inducing ADCC and / or CDC, wherein said polypeptides are substantially incapable of forming multimers linked by disulfide bonds. These fusion proteins with high levels of expression can be produced by recombinant methods. The present invention also describes related compositions and methods, including cell-surface forms of fusion proteins, and the use of fusion proteins and polynucleotides encoding such fusion proteins in immunotherapy. |